Home > Resources > Whitepapers > No Patient Left Behind – Connecting Rare Disease Patients to Orphan Drug Manufacturers

No Patient Left Behind – Connecting Rare Disease Patients to Orphan Drug Manufacturers

July 28, 2016

If you have ever worked with Orphan Drugs, you know finding appropriate patients is a major commercial challenge. Pharmaceutical sponsors of Orphan Drugs often lack the infrastructure and capabilities necessary to identify physicians who diagnose, treat, and manage these rare patients. TrialCard developed a proven model for making this critical match and has helped many patients gain access to the therapy they so desperately need.

Spotlight

Orbona Pharma Ltd

Orbona Pharma Ltd is a privately held start up specialist pharmaceutical company dedicated to improving the lives’ of children with rare diseases. Established in late 2011 Orbona Pharma is developing two late stage drugs to treat a number of Orphan diseases. Between 50%-90% of medicines administered to children have not been developed for them (source: EMA and Eurodis) and often Medicines used are those for adults; administered to children by decreasing quantities based on weight, which can be extremely hazardous and is far from ideal. Orbona Pharma is working to address this. Orbona Pharma is working on two late stage drugs in oncology and immunology and is developing a pipeline of other candidates for development. Based in the UK, but with a network of experienced professionals in Europe, the US and elsewhere, Orbona is working hard to establish a global presence.

OTHER WHITEPAPERS

DEVELOPING AND OPTIMIZING CLEANING PROCESSES

whitePaper | November 1, 2022

Equipment cleaning in manufacturing companies is often not given the same emphasis as other processes. It can be viewed as a task.

A pragmatic approach to developing rare disease drug

whitePaper | July 13, 2023

Most medicines in development today target diseases affecting large sections of the global population. But now we are slowly beginning to see a rise in the interest of developing ”orphan drugs,” or pharmaceutical agents intended to treat rare diseases.

Asia Pacific – Clinical trial landscape

whitePaper | November 8, 2022

The Asia-Pacific region has emerged as a clinical trial hub due to the ease of regulatory compliance, low trial costs, rising patient population, and the availability of top clinical institutions.

Vendor Partnering in a Bioprocess Manufacturing and Supply Chain Ecosystem

whitePaper | October 14, 2022

Supply constancy, cost, sterility – even a subset of the factors that impact materials selection can be daunting for biopharmaceutical companies embarking on a new drug development project.

Strengthening Engagement and Influence with Key Decision Makers

whitePaper | January 5, 2023

This report follows up on the jointly hosted Pharmaforce and elandas webinar which took place on July, 12, 2016, featuring contributions from participating industry leaders who formed the expert panel, as well as the live contributions of the audience of healthcare sales and marketing professionals.

A Comparison of Substance Use Disorders before and during theCOVID-19 Pandemic

whitePaper | September 22, 2022

During the COVID-19 pandemic, drug overdose deaths have increased. At the same time, access to and utilization of substance use disorder treatment services have decreased.

DEVELOPING AND OPTIMIZING CLEANING PROCESSES

whitePaper | November 1, 2022

Equipment cleaning in manufacturing companies is often not given the same emphasis as other processes. It can be viewed as a task.

A pragmatic approach to developing rare disease drug

whitePaper | July 13, 2023

Asia Pacific – Clinical trial landscape

whitePaper | November 8, 2022

The Asia-Pacific region has emerged as a clinical trial hub due to the ease of regulatory compliance, low trial costs, rising patient population, and the availability of top clinical institutions.

Vendor Partnering in a Bioprocess Manufacturing and Supply Chain Ecosystem

whitePaper | October 14, 2022

Supply constancy, cost, sterility – even a subset of the factors that impact materials selection can be daunting for biopharmaceutical companies embarking on a new drug development project.

Strengthening Engagement and Influence with Key Decision Makers

whitePaper | January 5, 2023

This report follows up on the jointly hosted Pharmaforce
and elandas webinar which took place on July, 12,
2016, featuring contributions from participating industry
leaders who formed the expert panel, as well as the live
contributions of the audience of healthcare sales and
marketing professionals.

A Comparison of Substance Use Disorders before and during theCOVID-19 Pandemic

whitePaper | September 22, 2022

During the COVID-19 pandemic, drug overdose deaths have increased. At the same time, access to and utilization of substance use disorder treatment services have decreased.

More Whitepapers

No Patient Left Behind – Connecting Rare Disease Patients to Orphan Drug Manufacturers

Spotlight

Orbona Pharma Ltd

OTHER WHITEPAPERS

DEVELOPING AND OPTIMIZING CLEANING PROCESSES

A pragmatic approach to developing rare disease drug

Asia Pacific – Clinical trial landscape

Vendor Partnering in a Bioprocess Manufacturing and Supply Chain Ecosystem

Strengthening Engagement and Influence with Key Decision Makers

A Comparison of Substance Use Disorders before and during theCOVID-19 Pandemic

DEVELOPING AND OPTIMIZING CLEANING PROCESSES

A pragmatic approach to developing rare disease drug

Asia Pacific – Clinical trial landscape

Vendor Partnering in a Bioprocess Manufacturing and Supply Chain Ecosystem

Strengthening Engagement and Influence with Key Decision Makers

A Comparison of Substance Use Disorders before and during theCOVID-19 Pandemic

Spotlight

Orbona Pharma Ltd

Events

National Medtech & Biotech Summit 2024

2024 AAPS NATIONAL BIOTECHNOLOGY CONFERENCE

National Medtech & Biotech Summit 2024

2024 AAPS NATIONAL BIOTECHNOLOGY CONFERENCE